New Delhi: Drug company Lupine on Friday said it has received approval from the US health regulator to market a generic drug to treat seizures.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug company said in a statement.
It states that this product is manufactured by Supernus Pharmaceuticals, Inc. K is a generic equivalent of Trokendi XR extended-release capsules.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
According to IQVIA MAT, topiramate extended-release capsules had estimated annual sales in the US of US$253 million.
Lupine shares closed at Rs 1,798, down 1.04 per cent, on the BSE.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug company said in a statement.
It states that this product is manufactured by Supernus Pharmaceuticals, Inc. K is a generic equivalent of Trokendi XR extended-release capsules.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
According to IQVIA MAT, topiramate extended-release capsules had estimated annual sales in the US of US$253 million.
Lupine shares closed at Rs 1,798, down 1.04 per cent, on the BSE.
